Amphastar Pharma (AMPH) Tops Q2 EPS by 2c

Amphastar Pharma (NASDAQ: AMPH) reported Q2 EPS of ($0.09), $0.02 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $53.85 million versus the consensus estimate of $55.7 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
• Archrock names Mohit Singh as CFO, effective July 6
• BMO Capital on FedEx (FDX): 'Guidance Appears Consistent With Our Forecasts'